ImmunityBio (IBRX) Cash from Operations Growth (3y) (2017 - 2026)
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Ops. Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | - |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | 37.40% |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | 20.11% |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | 16.64% |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | -7.60% |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | 34.32% |
| 10 | ImmunityBio | 7.72 Bn | 7.34 Bn | 43.97 Mn | 3.65% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 3.65% |
| Dec 31, 2025 | 8.12% |
| Sep 30, 2025 | 5.11% |
| Jun 30, 2025 | 4.37% |
| Mar 31, 2025 | -4.66% |
| Dec 31, 2024 | -5.93% |
| Sep 30, 2024 | -10.74% |
| Jun 30, 2024 | -12.97% |
| Mar 31, 2024 | -20.95% |
| Dec 31, 2023 | -26.02% |
| Sep 30, 2023 | -33.19% |
| Jun 30, 2023 | -20.12% |
| Mar 31, 2023 | -39.42% |
| Dec 31, 2022 | 4.94% |
| Sep 30, 2022 | -69.43% |
| Jun 30, 2022 | -75.69% |
| Mar 31, 2022 | -78.94% |
| Dec 31, 2021 | -72.19% |
| Sep 30, 2021 | -60.55% |
| Jun 30, 2021 | -62.34% |
| Mar 31, 2021 | -57.39% |
| Dec 31, 2020 | -61.64% |
| Sep 30, 2020 | -53.98% |
| Jun 30, 2020 | -45.47% |
| Mar 31, 2020 | -45.70% |
| Dec 31, 2019 | -114.17% |
| Sep 30, 2019 | -15.76% |
| Jun 30, 2019 | -26.56% |
| Mar 31, 2019 | -13.88% |
| Dec 31, 2018 | -8.64% |
| Sep 30, 2018 | -61.15% |
| Jun 30, 2018 | -79.98% |
| Mar 31, 2018 | -28.14% |
| Dec 31, 2017 | -74.34% |
| Sep 30, 2017 | -137.86% |
| Jun 30, 2017 | -93.83% |
| Mar 31, 2017 | -542.04% |